Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 124 clinical trials
BrUOG 390: Neoadjuvant Treatment With Talazoparib

Ovarian cancer is the most fatal gynecologic cancer; in the US alone an estimated 22,000 women will be diagnosed in 2019, with over 13,000 dying of the disease. Approximately half of epithelial ovarian cancers (EOC) exhibit defective DNA repair through alterations in the homologous recombination (HR) pathway, with 14% accounted …

fallopian tube
ovarian cancer
x-rays
carcinoma
breast cancer
  • 0 views
  • 25 Jul, 2022
  • 2 locations
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations. The names of the study drugs involved in this study are: Niraparib (Zejula) Dostarlimab

estrogen receptor
BRCA1
HER2
core needle biopsy
breast carcinoma
  • 0 views
  • 12 Jul, 2022
  • 4 locations
Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features (FPPCN)

selected high-risks patients with strong family history of pancreatic cancer and/or certain germline mutations of pancreatic cancer susceptibility genes (eg, BRCA1, BRAC2, DNA mismatch repair genes in

Accepts healthy volunteers
  • 0 views
  • 30 Apr, 2022
  • 1 location
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to testosterone suppression) with homologous recombination DNA repair deficiency. Chemotherapy drugs, such as docetaxel and carboplatin, work to stop the …

glomerular filtration rate
cancer
sipuleucel-t
testosterone
antiandrogen therapy
  • 28 views
  • 30 Jun, 2022
  • 1 location
A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This phase Ib trial studies the best dose and side effects of niraparib and copanlisib in treating patients with endometrial, ovarian, primary peritoneal, or fallopian tube cancer that has come back. Niraparib and copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell …

fallopian tube
cancer
ovarian cancer
maintenance therapy
neutrophil count
  • 576 views
  • 15 Sep, 2022
  • 1 location
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell …

cancer
luteinizing hormone (lh)
olaparib
blood transfusion
serum pregnancy test
  • 0 views
  • 29 May, 2022
  • 5 locations
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

This phase I/II trial studies the side effects and best dose of liposomal irinotecan and rucaparib when given together with fluorouracil and leucovorin calcium and to see how well they work in treating patients with pancreatic, colorectal, gastroesophageal, or biliary cancer that has spread to other places in the body …

metastasis
cancer
metastatic adenocarcinoma
platelet count
leucovorin
  • 8 views
  • 16 Jun, 2022
  • 3 locations
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking …

cancer
rad51c
fancl
platelet count
prostatectomy
  • 6 views
  • 21 Mar, 2022
  • 1 location
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

This phase II trial studies how well olaparib with cediranib or AZD6738 works in treating patients with germline BRCA mutated breast cancer that has spread to other places in the body (advanced or metastatic). Olaparib, cediranib, and AZD6738 may stop the growth of tumor cells by blocking some of the …

metastasis
cancer
endocrine therapy
liver metastasis
platelet count
  • 0 views
  • 19 Apr, 2022
  • 1 location
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

PARP inhibitors have changed the treatment paradigm of ovarian cancer. Most patients using PARP(poly-ADP ribose polymerase) inhibitors will suffer different grades of adverse events(AEs), followed by dose reduction. It has not been reported whether the dose-reduced olaparib as maintenance treatment have an impact on efficacy. Both PAOLA-1 and AVANOVA 2 …

fallopian tube
cancer
metastasis
ovarian cancer
chemotherapy regimen
  • 5 views
  • 27 Jan, 2021
  • 1 location